105 related articles for article (PubMed ID: 30648436)
1. Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.
Shen Y; Crassini K; Sandhu S; Fatima N; Christopherson RI; Mulligan SP; Best OG
Leuk Lymphoma; 2019 Jul; 60(7):1632-1643. PubMed ID: 30648436
[TBL] [Abstract][Full Text] [Related]
2. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
3. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.
Wang X; Zhang X; Li BS; Zhai X; Yang Z; Ding LX; Wang H; Liang C; Zhu W; Ding J; Meng LH
Oncotarget; 2014 Nov; 5(21):10732-44. PubMed ID: 25313141
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
6. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
Ding W; Shanafelt TD; Lesnick CE; Erlichman C; Leis JF; Secreto C; Sassoon TR; Call TG; Bowen DA; Conte M; Kumar S; Kay NE
Br J Haematol; 2014 Jan; 164(1):146-50. PubMed ID: 24111951
[No Abstract] [Full Text] [Related]
7. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
Crassini K; Pyke T; Shen Y; Stevenson WS; Christopherson RI; Mulligan SP; Best OG
Leuk Lymphoma; 2018 Dec; 59(12):2917-2928. PubMed ID: 29911936
[TBL] [Abstract][Full Text] [Related]
9. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
11. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
12. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
[TBL] [Abstract][Full Text] [Related]
13. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
[TBL] [Abstract][Full Text] [Related]
14. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
15. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K
Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802
[TBL] [Abstract][Full Text] [Related]
16. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.
Herishanu Y; Gibellini F; Njuguna N; Hazan-Halevy I; Farooqui M; Bern S; Keyvanfar K; Lee E; Wilson W; Wiestner A
Leuk Lymphoma; 2011 Sep; 52(9):1758-69. PubMed ID: 21649540
[TBL] [Abstract][Full Text] [Related]
17. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer SW; Piñón JD; Brachtl G; Haginger L; Wang W; Jöhrer K; Tinhofer I; Hartmann TN; Greil R
Cancer Res; 2010 Sep; 70(18):7336-44. PubMed ID: 20823161
[TBL] [Abstract][Full Text] [Related]
18. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
[TBL] [Abstract][Full Text] [Related]
19. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.
Krysov S; Dias S; Paterson A; Mockridge CI; Potter KN; Smith KA; Ashton-Key M; Stevenson FK; Packham G
Blood; 2012 Jan; 119(1):170-9. PubMed ID: 22086413
[TBL] [Abstract][Full Text] [Related]
20. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Kim E; Ten Hacken E; Sivina M; Clarke A; Thompson PA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG; Bhalla KN; Burger JA
Leukemia; 2020 Jun; 34(6):1588-1598. PubMed ID: 31862959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]